PKDREJ Inhibitors
PKDREJ inhibitors represent a class of chemical compounds that target the protein kinase domain receptor for the Juno receptor (PKDREJ). PKDREJ is a member of the sperm protein family that is implicated in cellular signaling processes, specifically in reproductive biology. The protein has a unique structure that includes both kinase-like and receptor domains, although it has been shown that its kinase domain lacks catalytic activity. Instead, PKDREJ functions primarily as a scaffold for the organization of other signaling molecules. The inhibitors of PKDREJ are therefore designed to interfere with its ability to mediate cellular interactions, particularly in processes involving membrane dynamics and signal transduction. These inhibitors are typically small molecules that bind to critical regions of PKDREJ, thereby modulating its interactions with other proteins or preventing its association with signaling complexes.
From a structural perspective, PKDREJ inhibitors are designed to target the unique surface features and non-catalytic binding sites of the receptor. The interactions between these inhibitors and PKDREJ often involve hydrophobic pockets or allosteric sites, which are regions of the protein critical for maintaining its conformational state. By binding to these regions, PKDREJ inhibitors can alter the structural integrity of the protein, leading to changes in its function at the molecular level. Such alterations can affect downstream signaling pathways in a variety of cellular contexts, particularly those involved in membrane fusion, receptor-mediated signaling, and other aspects of cell communication. The study of PKDREJ inhibitors has contributed to a better understanding of protein-protein interactions, signal transduction mechanisms, and the regulation of non-catalytic kinases.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A may downregulate PKDREJ by enhancing histone acetylation, leading to a loosened chromatin structure that could suppress the initiation of transcription at the PKDREJ gene locus. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
By incorporating into DNA and inhibiting methyltransferases, 5-Azacytidine could reduce methylation levels at the PKDREJ gene promoter, which might decrease PKDREJ transcription. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 may decrease PKDREJ expression by inhibiting the PI3K/Akt pathway, which is often involved in promoting transcription of growth-related genes, potentially including PKDREJ. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 specifically inhibits MEK, which is part of the MAPK/ERK pathway, potentially leading to decreased phosphorylation and activation of transcription factors that drive PKDREJ expression. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib might reduce PKDREJ expression by preventing the degradation of inhibitory proteins that control transcription factor availability, thereby indirectly decreasing transcription. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin could inhibit PKDREJ expression by specifically targeting mTOR, a central protein in a signaling pathway known to control the translation of a broad array of mRNAs. | ||||||
D,L-Sulforaphane | 4478-93-7 | sc-207495A sc-207495B sc-207495C sc-207495 sc-207495E sc-207495D | 5 mg 10 mg 25 mg 1 g 10 g 250 mg | $153.00 $292.00 $489.00 $1325.00 $8465.00 $933.00 | 22 | |
DL-Sulforaphane might decrease PKDREJ expression by inhibiting the activation of the NF-kB pathway, which is associated with the transcriptional control of numerous genes, potentially including PKDREJ. | ||||||
Pladienolide B | 445493-23-2 | sc-391691 sc-391691B sc-391691A sc-391691C sc-391691D sc-391691E | 0.5 mg 10 mg 20 mg 50 mg 100 mg 5 mg | $299.00 $5699.00 $11099.00 $25500.00 $66300.00 $2875.00 | 63 | |
Pladienolide B could inhibit the splicing of PKDREJ pre-mRNA, leading to an accumulation of unprocessed mRNA that would not be translated into functional protein. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 may downregulate PKDREJ by competitively binding to bromodomains of BET proteins, displacing them from chromatin and reducing the transcriptional elongation of target genes. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
5-Aza-2′-Deoxycytidine may lead to a decrease in PKDREJ expression levels by causing DNA hypomethylation, which can silence gene expression when occurring in gene promoter regions. | ||||||